01/19/2026
Cure ATRT Now are deeply grateful for your continued support as we enter the next phase of funding a drug development effort to target DCAF5.
We could not sustain our efforts without your generous support.
On Jan 12th, 2026, we were thrilled to be able to donate $75,000 to Dr. Charlie Roberts. Below is an excerpt from his recent report regarding how your donations are working to find a Cure.
From the bottom of our hearts, we thank you 🙏💜
“Research into atypical teratoid/rhabdoid tumors (ATRT) has reached a pivotal moment with the discovery of DCAF5 as a selective and druggable therapeutic target, showing that DCAF5 inhibition kills ATRT/rhabdoid tumor cells while sparing normal tissue—an essential advance for pediatric cancer therapy.
This finding, published in “Nature “ in 2024, energized the field, leading Cancer Research UK to rank ATRT/rhabdoid tumors as the top unmet pediatric cancer need and DCAF5 as the most promising target. A world-class academic collaboration has since launched a phased drug-development effort, already identifying multiple DCAF5 docking sites and promising lead compounds for clinical advancement.
This progress was enabled by foundational support from Cure ATRT Now, whose sustained investment made possible the laboratory models and early research that led to the DCAF5 discovery and
now drives preclinical development. Together, these advances mark a meaningful shift in ATRT research and represent a powerful legacy in honor of Avalanna.